Exosens SAS/ADR
No enriched coverage for $EXOSF in the last 7 days.
No SEC Form 4 filings for $EXOSF in the last 30 days.
See all $EXOSF insider activity →Exosens stock fell 6% to €56.10 after Q3 2026 revenue growth of 23.5% YoY and 18% for nine months, but investors were disappointed by unchanged guidance and a 50.4% adjusted gross margin. The broader market downturn also contributed to the decline.
Exosens reported 9-month 2026 revenue of €386.9M, up 18.0% YoY, with Q3 growth at 23.5%. Adjusted gross margin was €194.9M (50.4%). The company stated it is on track to meet its upgraded 2026 guidance.
Exosens supplied neutron detectors to Antares Nuclear and Valar Atomics for DOE reactor demos, anticipating pre-series orders and long-term U.S. demand for its nuclear instrumentation.
Recent EXOSF coverage spans earnings, technology and financial news.
Exosens stock fell 6% to €56.10 after Q3 2026 revenue growth of 23.5% YoY and 18% for nine months, but investors were disappointed by unchanged guidance and a 50.4% adjusted gross margin. The broader market downturn also contributed to the decline.
Exosens reported 9-month 2026 revenue of €386.9M, up 18.0% YoY, with Q3 growth at 23.5%. Adjusted gross margin was €194.9M (50.4%). The company stated it is on track to meet its upgraded 2026 guidance.
Exosens supplied neutron detectors to Antares Nuclear and Valar Atomics for DOE reactor demos, anticipating pre-series orders and long-term U.S. demand for its nuclear instrumentation.
Exosens (EXENS) stock surged 12.1% to €60.90 after revising its 2026 outlook, raising revenue guidance to €558M-€570M from €520M-€540M and EBITDA to €186M-€192M from €168M-€178M. CEO Jerome Cerisier cited faster production ramp-up. No analyst upgrades or insider transactions were reported. The broader market was supportive, with global indices trading higher.
Exosens' subsidiary, Photonis Defense, received a $1.6B order for 1,600 BiNOD systems from the U.S. Army, marking a key milestone in Exosens' U.S. expansion. Deliveries are expected by the end of 2026, with the bulk in 2027. The order supports the BiNOD program's Low-Rate Initial Production phase, leveraging Photonis Defense's U.S. production capabilities and Exosens' technology leadership. Financial terms were not disclosed.
AlphAI scores every news story that mentions EXOSF with an AI model for sentiment and relevance, and aggregates insider trades from Exosens SAS/ADR's SEC EDGAR Form 4 filings. Figures refresh continuously.
Exosens stock fell 6% to €56.10 after Q3 2026 revenue growth of 23.5% YoY and 18% for nine months, but investors were disappointed by unchanged guidance and a 50.4% adjusted gross margin. The broader market downturn also contributed to the decline.
2 min readExosens reported 9-month 2026 revenue of €386.9M, up 18.0% YoY, with Q3 growth at 23.5%. Adjusted gross margin was €194.9M (50.4%). The company stated it is on track to meet its upgraded 2026 guidance.
1 min readExosens supplied neutron detectors to Antares Nuclear and Valar Atomics for DOE reactor demos, anticipating pre-series orders and long-term U.S. demand for its nuclear instrumentation.
1 min readExosens (EXENS) stock surged 12.1% to €60.90 after revising its 2026 outlook, raising revenue guidance to €558M-€570M from €520M-€540M and EBITDA to €186M-€192M from €168M-€178M. CEO Jerome Cerisier cited faster production ramp-up. No analyst upgrades or insider transactions were reported. The broader market was supportive, with global indices trading higher.
2 min readExosens' subsidiary, Photonis Defense, received a $1.6B order for 1,600 BiNOD systems from the U.S. Army, marking a key milestone in Exosens' U.S. expansion. Deliveries are expected by the end of 2026, with the bulk in 2027. The order supports the BiNOD program's Low-Rate Initial Production phase, leveraging Photonis Defense's U.S. production capabilities and Exosens' technology leadership. Financial terms were not disclosed.
2 min readExosens (EPA: EXENS) reported H1 fiscal 2026 adjusted EBIT of €71m, above the €67m forecast, up 19.2% YoY, with a 28.4% margin. Revenue was €253m, slightly below €254m consensus, but up 11.4% YoY. Q2 revenue was €130.5m. It reaffirmed FY2026 guidance: revenue €520-540m and adjusted EBITDA €168-178m, aiming for upper-end results.
4 min read
